©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Oct 27, 2024; 16(10): 3087-3090
Published online Oct 27, 2024. doi: 10.4240/wjgs.v16.i10.3087
Published online Oct 27, 2024. doi: 10.4240/wjgs.v16.i10.3087
Urgent need for prognostic markers for hepatocellular carcinoma in the light of genomic instability and non-coding RNA signatures
Tsvetelina Velikova, Milena Gulinac, Medical Faculty, Sofia University Street Kliment Ohridski, Sofia 1407, Bulgaria
Milena Gulinac, General and Clinical Pathology, Medical University of Plovdiv, Plovdiv 4002, Bulgaria
Co-first authors: Tsvetelina Velikova and Milena Gulinac.
Author contributions: Velikova T and Gulinac M wrote the paper; Velikova T revised the paper. Both authors approved the final version of the manuscript before submission.
Supported by The European Union-Next Generation EU , through the National Recovery and Resilience Plan of the Republic of Bulgaria, No. BG-RRP-2.004-0008.
Conflict-of-interest statement: The authors declare no conflict of interest.
Corresponding author: Milena Gulinac, MD, PhD, Academic Research, General and Clinical Pathology, Medical University of Plovdiv, 15A Vassil Aprilov Blvd, Plovdiv 4002, Bulgaria. mgulinac@hotmail.com
Received: April 8, 2024
Revised: May 12, 2024
Accepted: July 8, 2024
Published online: October 27, 2024
Processing time: 173 Days and 4.6 Hours
Revised: May 12, 2024
Accepted: July 8, 2024
Published online: October 27, 2024
Processing time: 173 Days and 4.6 Hours
Core Tip
Core Tip: Despite challenges in diagnosing and treating hepatocellular carcinoma (HCC), identifying suitable prognostic factors is crucial. Duan et al proposed a novel approach using long non-coding RNAs (LncRNAs) to quantify genomic instability (GI) in HCC. Their study demonstrated that the GI-derived LncRNA signature is an independent prognostic factor, outperforming TP53 mutation status alone with an area under the curve of 0.773. These findings underscore the importance of exploring genetic markers for predicting HCC prognosis, aiding in identifying therapeutic targets and improving diagnostic and treatment strategies to alleviate the global burden of this disease.